Get the Stockscreener App
0.7749
0.10%
0.0008
After Hours:
.79
0.0151
+1.95%
Bioatla Inc stock is traded at $0.7749, with a volume of 1.60M.
It is up +0.10% in the last 24 hours and up +109.38% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$0.7741
Open:
$0.8
24h Volume:
1.60M
Relative Volume:
2.19
Market Cap:
$45.50M
Revenue:
-
Net Income/Loss:
$-123.46M
P/E Ratio:
-0.2992
EPS:
-2.59
Net Cash Flow:
$-104.11M
1W Performance:
+44.44%
1M Performance:
+109.38%
6M Performance:
+131.24%
1Y Performance:
-55.21%
1-Day Range:
$0.75
$0.84
1-Week Range:
$0.53
$0.84
52-Week Range:
$0.2601
$2.525
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.7749 | 39.23M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
Key metrics from BioAtla Inc.’s quarterly dataTrade Signal Summary & Daily Chart Pattern Signal Reports - Newser
Will BioAtla Inc. benefit from macro trends2025 Growth vs Value & Real-Time Volume Triggers - Newser
Is BioAtla Inc. stock ready for a breakout2025 Major Catalysts & Weekly Sector Rotation Insights - Newser
Can BioAtla Inc. recover in the next quarter2025 Key Lessons & AI Forecasted Entry and Exit Points - Newser
Short interest data insights for BioAtla Inc.Earnings Risk Report & Weekly Watchlist for Consistent Profits - Newser
Earnings visualization tools for BioAtla Inc.2025 Earnings Surprises & Technical Buy Zone Confirmations - Newser
BioAtla Inc.’s volatility index tracking explainedQuarterly Market Review & Technical Confirmation Alerts - Newser
Using Bollinger Bands to evaluate BioAtla IncMarket Performance Summary & Consistent Profit Focused Trading Strategies - Newser
Published on: 2025-09-12 13:57:40 - Newser
What machine learning models say about BioAtla Inc.Weekly Profit Summary & Fast Moving Stock Watchlists - Newser
Is BioAtla Inc. stock reversal real or fake2025 Price Targets & Weekly High Return Opportunities - Newser
Risk adjusted return profile for BioAtla Inc. analyzedInsider Buying & Technical Entry and Exit Tips - Newser
Applying chart zones and confluence areas to BioAtla Inc.2025 Price Targets & Daily Market Momentum Tracking - Newser
When is the best time to exit BioAtla Inc.2025 Market WrapUp & Growth Focused Stock Reports - Newser
How to monitor BioAtla Inc. with trend dashboardsBuy Signal & Momentum Based Trading Signals - Newser
Tick level data insight on BioAtla Inc. volatilityEarnings Overview Summary & Short-Term Swing Trade Alerts - Newser
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma Following Productive Type B Meeting with FDA - Investing News Network
BioAtla stock holds Market Perform rating at JMP as FDA aligns on Phase 3 design By Investing.com - Investing.com South Africa
BioAtla stock holds Market Perform rating at JMP as FDA aligns on Phase 3 design - Investing.com Canada
Will BioAtla Inc. rebound enough to break evenEarnings Overview Report & High Return Stock Watch Alerts - Newser
BioAtla announces outcomes from Type B FDA meeting on ozuriftamab vedotin - TipRanks
Tools to monitor BioAtla Inc. recovery probabilityMarket Movers & Fast Gain Swing Trade Alerts - Newser
What institutional flow reveals about BioAtla Inc.Trend Reversal & Capital Protection Trade Alerts - Newser
FDA aligns with BioAtla on phase 3 trial design for cancer drug By Investing.com - Investing.com South Africa
Is BioAtla Inc. forming a breakout patternJobs Report & Long-Term Safe Investment Ideas - beatles.ru
FDA aligns with BioAtla on phase 3 trial design for cancer drug - Investing.com Canada
BioAtla Inc. Reversal Rally May Surprise BearsJuly 2025 Analyst Calls & Weekly Breakout Stock Alerts - beatles.ru
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):